Why did AstraZeneca acquire Alexion?

Why did AstraZeneca acquire Alexion?

Together, we have the opportunity to add more value for more patients worldwide across a full-spectrum of care. Alexion’s innovative complement-biology platforms and robust pipeline place AstraZeneca in a strong position for enhancing its scientific presence in the immunology sector.

What did AstraZeneca pay for Alexion?

AstraZeneca is splashing out $39 billion to buy Alexion in a cash-and-stock deal, the British pharma revealed Saturday. The deal is driven by AstraZeneca’s desire to build a stronger presence in immunology—and to give its top line an immediate boost.

Did AstraZeneca buy Alexion Pharmaceuticals?

AstraZeneca’s mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.

Who is buying Alexion?

AstraZeneca
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push.

What happened to Alexion Pharmaceuticals stock?

The Alexion shares will be delisted from the Nasdaq Stock Market and Alexion will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition.

What is the Alexion deal?

The $39bn deal, announced in December 2020, is AstraZeneca’s largest ever acquisition: allowing it to move further into immunology with an enhanced scientific presence, and giving it Alexion’s lead medicine soliris (eculizumab), among four other approved medicines and a pipeline of 11 molecules.

Should I buy Alexion?

The consensus among Wall Street analysts is that investors should “hold” Alexion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares.

When did AstraZeneca buy Alexion?

AstraZeneca expects to complete its $39 billion acquisition of Alexion on July 21 after receiving the last regulatory clearance it needed, from the U.K. Competition and Markets Authority.

Who owns Alexion Pharmaceuticals?

Alexion Pharmaceuticals/Parent organizations

What does Alexion Pharma do?

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma.

What’s the price of Alexion stock?

Shares in Alexion Pharmaceuticals Inc are currently trading at $182.5 and the price has moved by 66.61\% over the past 365 days.

When was Alexion acquired by AstraZeneca?

Why did AstraZeneca buy Alexion for $39 billion?

Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest-ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs.

How will the AstraZeneca-AstraZeneca deal affect the company?

AstraZeneca said it expected the deal to immediately boost core earnings and to deliver pretax synergy gains of around $500 million per year. It also expects around $650 million in one-time cash costs during the three years following completion.

What does AstraZeneca do?

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

When will the AstraZeneca-Oxford merger complete?

Regulatory hurdles that come with big international mergers are expected to keep this one from completing until the third quarter of 2021. Based on yesterday’s closing prices for both stocks, though, AstraZeneca’s offer represents a 45\% premium.